Literature DB >> 25628098

Status epilepticus developing during lacosamide monotherapy.

Savvas S Papacostas1.   

Abstract

Two cases with partial onset epilepsy who developed status epilepticus (SE) on lacosamide (LCM) monotherapy are reported. LCM is an effective adjunctive antiepileptic drug (AED) for partial-onset epilepsy and as infusion in SE. It has also shown efficacy in monotherapy. The reported cases achieved control of seizures with adjunctive LCM treatment and were afterwards converted to monotherapy. Both patients subsequently developed SE while on LCM monotherapy. They were on monotherapy for at least 2 months after withdrawal of concomitant AEDs precluding the possibility of withdrawal-induced SE. Pharmacovigilance is indicated when LCM is administered in monotherapy in order to assess its proper therapeutic potential and its putative limitations especially in cases where it may prove ineffective. Moreover, vigilance is necessary whenever any concomitant antiepileptic is tapered regardless of the substances used. Higher doses may be needed when an AED is used in monotherapy. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25628098      PMCID: PMC4322243          DOI: 10.1136/bcr-2014-206354

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.

Authors:  John-Kenneth Sake; David Hebert; Jouko Isojärvi; Pamela Doty; Marc De Backer; Kendra Davies; Andrea Eggert-Formella; James Zackheim
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

Review 2.  Lacosamide.

Authors:  Pamela Doty; G David Rudd; Thomas Stoehr; Dirk Thomas
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  Lacosamide use in refractory idiopathic primary generalized epilepsy.

Authors:  Andro Zangaladze; Christopher Skidmore
Journal:  Epilepsy Behav       Date:  2011-12-23       Impact factor: 2.937

Review 5.  Lacosamide for the treatment of partial-onset seizures.

Authors:  Victor Biton
Journal:  Expert Rev Neurother       Date:  2012-06       Impact factor: 4.618

6.  Adjunctive lacosamide in clinical practice: sodium blockade with a difference?

Authors:  Linda J Stephen; Kevin Kelly; Pamela Parker; Martin J Brodie
Journal:  Epilepsy Behav       Date:  2011-09-03       Impact factor: 2.937

7.  The safety of lacosamide for treatment of seizures and seizure prophylaxis in adult hospitalized patients.

Authors:  Marilyn E Luk; William O Tatum; Alden V Patel; Karen M Nau; William D Freeman
Journal:  Neurohospitalist       Date:  2012-07

8.  Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice.

Authors:  Alexey Shandra; Pavel Shandra; Olga Kaschenko; Alain Matagne; Thomas Stöhr
Journal:  Epilepsia       Date:  2013-06-10       Impact factor: 5.864

9.  Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study.

Authors:  Robert T Wechsler; George Li; Jacqueline French; Terence J O'Brien; O'Neill D'Cruz; Paulette Williams; Robin Goodson; Melissa Brock
Journal:  Epilepsia       Date:  2014-06-10       Impact factor: 5.864

10.  Lacosamide adjunctive therapy for partial-onset seizures: a meta-analysis.

Authors:  Sonja C Sawh; Jennifer J Newman; Santosh Deshpande; Philip M Jones
Journal:  PeerJ       Date:  2013-08-06       Impact factor: 2.984

View more
  1 in total

1.  Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients.

Authors:  Edibe Pembegul Yildiz; Melis Ulak Ozkan; Gonca Bektas; Tuğçe Aksu Uzunhan; Nur Aydinli; Mine Caliskan; Meral Ozmen
Journal:  Childs Nerv Syst       Date:  2017-09-07       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.